This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

Pressure has been mounting for the Federal Trade Commission to take action, with Senator Elizabeth Warren last week urging ...

The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic ...